Low-dose 5-fluorouracil adjuvant in laser therapy for HPV lesions in immunosuppressed patients and cases of difficult control

The authors established a protocol for the use of 5-fluorouracil (5FU) adjuvant in lasertherapy for clinical and subclinical HPV infection in immunosuppressed patients, persistent lesions and as reinforcement treatment in cases of poor progress. Sixty-four patients were evaluated, of whom 26 were immunosuppressed, 34 presented persistent lesions and four received intravaginal reinforcement treatment with 2.5 g 5% 5FU every two weeks, or biweekly vulvar reinforcement after lasertherapy. On average, five 5FU courses were used, but in the immunossuppressed patients its use was maintained indefinitely. The rate of complete response was 66%, but the immunossuppressed patients showed less response (46.2%) when compared with the persistent lesion/reinforcement treatment group (78.9%). The responses were positive in the two groups when compared to that with no response. We deem the use of low-dose 5FU an excellent alternative in cases of difficult HPV progress, presenting a low cost and minimal side-effects.

5-fluorouracil; HPV

[1] Reid R., Greenberg M.D., Lorincz A .T., Daoud Y., Pizzuti D., Stoler M.: "Superficial laser vulvectomy. IV. Extended laser vaporization and adjuvant 5-fluorouracil therapy of human papillomavirus-associated vulvar disease". Obstet. Gynecol., 1990, 76, 439.

[2] Petry K.U., Scheffel D., Bode U., Gabrysiak T., K ochel H., Kupsch E. et al.: "Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions". Int. J Cancer, 1994, 57, 836.

[3] Sun X.W., Ellerbrock T.V., Lungu 0., Chiasson M. A., Bush T.J., Wright T.C.: "Human papillomavirus infection in human immunodeficiency virus-seroposititve women". Obstet. Gynecol., 1995, 85, 680.

[4] Silmann F.H., Boyce J.G., Macasaet M.A., Nicastri, A.D.: "5-fluorouracil/chemosurgery for intraepithelial neoplasia of the lower genital tract". Obstet. Gynecol., 1981, 58, 356.

[5] Ferenczy A.: "Comparisou of 5-fluorouracil and CO, laser for treatment of vaginal condylomata". Obstet. Gynecol., 1984, 64, 773.

[6] Krebs H.B.: "Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina". Obstet. Gynecol. 1986, 68, 837.

[7] Maiman M., Watts H., Andersen J., Clax P., Merino M., Kendall M.: "Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial". Obstet. Gynecol., 1999, 94, 954.

[8] Brodman M., Dottino P., Friedman F., Heller D., Bleiweiss I., Sperling R.: "Human pap仆lomavirus-associated lesions of the vagina and cervix treatment with a laser and topical 5-fluorouracil". J. Reprod. Med., 1992, 35, 453.

[9] Gonzalez Sanchez J.L., Flores Murrieta G., Chavez Brambila J., Deolarte Manzano J.M., Andrade Manzano A.F.: "Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms" Ginecol. Obstet. Mex., 2002, 70, 244.

[10] Syed T.A., Qureshi Z.A., Ahmad S.A., Ali S.M.: "Management of intra vaginal warts in women with 5-fluorouracil (1 %) in vaginal hydroph山c gel: a placebo-controlled double-blind study". Int. J STD & AIDS, 2000, 11, 371.